Caribou Biosciences (CRBU) catalysts

Upcoming FDA decisions and readouts we track for Caribou Biosciences, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Caribou Biosciences (CRBU, listed on Nasdaq). It concerns CB-011 (Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)).

First on the list: the Phase 1 readout for CB-011 (Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)), guided by the company to H2 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: CRBU
Next catalyst: H2 2026
Type: Phase 1 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Caribou Biosciences CRBU · Nasdaq	CB-011	Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)	H2 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up," plus longer follow-up on the 12-patient BCMA-naive dose-escalation cohort. Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
C4 Therapeutics (CCCC)Multiple myeloma — dose escalation progress; Multiple myeloma — biomarker data at IMS Annual Meeting; Multiple myeloma; Relapsed/refractory multiple myeloma
Cartesian Therapeutics (RNAC)Myasthenia gravis (mRNA CAR-T); Myositis; Juvenile dermatomyositis (paediatric); Myasthenia gravis
Sana Biotechnology (SANA)Non-Hodgkin lymphoma (in vivo CAR-T)
Tempest Therapeutics (TPST)Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)